# 5. Acute Coronary Syndromes

![](https://i.imgur.com/kDXCluk.png)
**Ddx** (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)

•**Nonatherosclerotic coronary artery disease** (_JACC_ 2018;72:2231)

Spasm: Prinzmetal’s variant, cocaine-induced (6% of chest pain + cocaine use r/i for MI)

Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde extension (usually involving RCA → IMI) or mechanical (PCI, surgery, trauma)

Embolism (_Circ_ 2015;132:241): AF, thrombus/myxoma, endocard., prosth valve thrombosis

Vasculitis: Kawasaki syndrome, Takayasu arteritis, PAN, Churg-Strauss, SLE, RA

Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)

•**Ischemia w/o plaque rupture** (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN)

•**Direct myocardial injury:** myocarditis; Takotsubo/stress CMP; toxic CMP; cardiac contusion

**Clinical manifestations** (_JAMA_ 2015;314:1955)

•**Typical angina:** retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms; precip. by exertion, relieved by rest/ NTG. In ACS: new-onset, crescendo or at rest.

•**Associated symptoms:** dyspnea, diaphoresis, N/V, palpitations or light-headedness

•Many MIs (~20% in older series) are initially unrecognized b/c silent or atypical sx

•Atypical sxs (incl N/V & epig pain) ? more common in ♀, elderly, diabetes, inferior ischemia

**Physical exam**

•Signs of ischemia: S4, new MR murmur 2° pap. muscle dysfxn, paradoxical S2, diaphoresis

•Signs of heart failure: ↑ JVP, crackles in lung fields, ⊕ S3, HoTN, cool extremities

•Signs of other vascular disease: asymmetric BP, carotid or femoral bruits, ↓ distal pulses

**Diagnostic studies** (_NEJM_ 2017;376:2053)

•**ECG:** ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI & ∴ CAD

✔ ECG w/in 10 min of presentation, with any ∆ in sx & at 6–12 h; compare w/ baseline

STEMI dx w/ old LBBB: ≥1 mm STE _concordant_ w/ QRS (Se 73%, Sp 92%), STD ≥1 mm V1–V3 (Se 25%, Sp 96%), STE ≥5 mm _discordant_ w/ QRS (Se 31%, Sp 92%)

![](https://i.imgur.com/oSt4F5h.png)
If ECG non-dx & suspicion high, ✔ leads V7–V9 to assess distal LCX/RCA territory. ✔ R-sided precordial leads in IMI to help detect RV involvement (STE in V4R most Se). STE in III > STE in II and lack of STE in I or aVL suggest RCA rather than LCX culprit in IMI. STE in aVR suggests LM or prox LAD occlusion or diffuse ischemia.

•**Cardiac biomarkers:** ✔ Tn (pref. over CK-MB) at presentation & 3–6 h (? 1hr if hsTn); repeat if clinical or ECG ∆s; >99th %ile w/ rise and/or fall in appropriate clinical setting dx of AMI (see “Chest Pain”); in CKD, ↑ Tn still portends poor prognosis (_NEJM_ 2002;346:2047)

•If low prob, **stress test, CT angio** to r/o CAD; new wall motion abnl on TTE suggests ACS

•**Coronary angio** gold standard for epicardial CAD

**Prinzmetal’s (variant) angina**

•Coronary spasm → transient STE usually w/o MI (_but_ MI, AVB, VT can occur)

•Pts usually young, smokers, ± other vasospastic disorders (eg, migraines, Raynaud’s)

•Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done)

•Treatment: high-dose CCB & standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans

•Cocaine-induced vasospasm: CCB, nitrates, ASA; ? avoid βB, but labetalol appears safe
![](https://i.imgur.com/Ak4bNqr.png)

**Approach to triage**

•If hx, initial ECG & Tn non-dx, repeat ECG q15–30min × 1 h & Tn 3–6 h (? 1hr if hs) later

•If remain nl and low likelihood of ACS, search for alternative causes of chest pain

•If remain nl, have ruled out MI, _but_ if high suspicion for ACS based on hx, then still need to r/o UA w/ stress test to assess for inducible ischemia (or CTA to r/o epicardial CAD);

if low risk (eg, age ≤70; ∅ prior CAD, CVD, PAD; ∅ rest angina) can do before d/c from ED or as outPt w/in 72 h (0% mortality, <0.5% MI; _Ann Emerg Med_ 2006;47:427)

if not low risk, admit and initiate Rx for possible ACS and consider stress test or cath

![](https://i.imgur.com/x0BHVsp.png)

**Other early adjunctive therapy**

•**High-intensity statin therapy** (eg, atorva 80 mg qd; PROVE-IT TIMI 22, _NEJM_ 2004;350:1495); ↓ ischemic events w/ benefit emerging w/in wks (_JAMA_ 2001;285:1711 & _JACC_ 2005;46:1405); ↓ peri-PCI MI (_JACC_ 2010;56:1099); ? ↓ contrast-induced nephropathy (_NEJM_ 2019;380:2156)

•**Ezetimibe:** ↓ CV events when added to statin (IMPROVE-IT, _NEJM_ 2015;372:1500)

•**ACEI/ARB:** start once hemodynamics and renal function stable

Strong indication for ACEI if heart failure, EF <40%, HTN, DM, CKD; ~10% ↓ mortality, greatest benefit in ant. STEMI or prior MI (_Lancet_ 1994;343:1115 & 1995;345:669)

ARB appear ≈ ACEI (_NEJM_ 2003;349:20); give if contraindic to ACEI

•IABP: can be used for refractory angina when PCI not available

---

## **NSTE-ACS** (_CIRC_ 2014;130:e344)
_Key issues are antithrombotic regimen and invasive vs. conservative strategy_
### **Antiplatelet Therapy**
![](https://i.imgur.com/RSLFCyI.png)
~30% pop has ↓ fxn _CYP2C_1_9_ → ↑ CV events if PCI on clopi (_NEJM_ 2009;360:354)
### **Anticoagulant Therapy**
![](https://i.imgur.com/oOGPkdW.png)

**Coronary angiography** (_Circ_ 2014;130:e344)
•**Immediate/urgent coronary angiography** (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability

•**Invasive (INV) strategy** = routine angiography w/in 72 h

_Early (w/in 24 h) if:_ ⊕ Tn, ST ∆, GRACE risk score ([www.outcomes-massmed.org/grace](http://www.outcomes-massmed.org/grace)) >140 (_NEJM_ 2009;360:2165; _Circ_ 2018;138:2741)

_Delayed (ie, w/in 72 h) acceptable if w/o above features but w/:_ diabetes, EF <40%, GFR <60, post-MI angina, TRS ≥3, GRACE score 109–140, PCI w/in 6 mo, prior CABG

32% ↓ rehosp for ACS, nonsignif 16% ↓ MI, no ∆ in mortality c/w cons. (_JAMA_ 2008;300:71).

↑ peri-PCI MI counterbalanced by ↓↓ in spont. MI. Mortality benefit seen in some studies, likely only if cons. strategy w/ low rate of angio.

•**Conservative (CONS) strategy** = selective angio. Med Rx w/ pre-d/c stress test; angio only if recurrent ischemia or strongly ⊕ ETT. _Indicated for:_ low TIMI Risk Score, Pt or physician pref in absence of high-risk features, or low-risk women (_JAMA_ 2008;300:71).

![](https://i.imgur.com/4uH90Lu.png)
**Figure 1-2** Approach to UA/NSTEMI
![](https://i.imgur.com/zaxJVcD.png)

---
## **STEMI**

**Requisite STE (at J point)**

•≥2 contiguous leads w/ ≥1 mm (except for V2–V3: ≥2 mm in ♂ and ≥1.5 mm in ♀), or

•New or presumed new LBBB w/ compelling H&P, or

•True posterior MI: ST depression V1–V3 ± tall Rw w/ STE on posterior leads (V7–V9)

**Reperfusion (“time is muscle”)**

•In PCI-capable hospital, goal should be **primary PCI w/in 90 min** of 1st medical contact

•In non–PCI-capable hospital, consider _transfer_ to PCI-capable hospital (see below), o/w **fibrinolytic therapy** w/in 30 min of hospital presentation

•Do not let decision regarding _method_ of reperfusion delay _time_ to reperfusion

**Primary PCI** (_JACC_ 2013;61:e78 & 2016;67:1235)

•Definition: immediate PCI upon arrival to hospital or transfer for immediate PCI

•Indic: STE + sx onset w/in <12 h; ongoing ischemia 12–24 h after sx onset; shock

•Superior to lysis: 27% ↓ death, 65% ↓ reMI, 54% ↓ stroke, 95% ↓ ICH (_Lancet_ 2003;361:13)

•_Transfer_ to center for 1° PCI superior to lysis (_NEJM_ 2003;349:733), see below

•Routine thrombus aspiration: no benefit, ↑ stroke (_Lancet_ 2015;387:127; 2015;372:1389)

•Consider PCI of non-culprit lesions at time of primary PCI or planned staged procedure because appears to ↓ MACE vs. culprit alone (_NEJM_ 2013;369:1115; _JACC_ 2015;65:963); but may harm if cardiogenic shock (_NEJM_ 2018;379:1699)

![](https://i.imgur.com/ZM66Ago.png)

Adapted from ACC/AHA 2013 STEMI Guidelines (_Circ_ 2013;127:529)

**Fibrinolysis**

•Indic: STE/LBBB + sx <12 h (& >120 min before PCI can be done); benefit if sx >12 h less clear; reasonable if persist. sx & STE, hemodynamic instability or large territory at risk

•Mortality ↓ ~20% in anterior MI or LBBB and ~10% in IMI c/w ∅ reperfusion Rx

•Prehospital lysis (ie, ambulance): further 17% ↓ in mortality (_JAMA_ 2000;283:2686)

•~1% risk of ICH; high risk incl elderly (~2% if >75 y), ♀, low wt. ∴ PCI more attractive

![](https://i.imgur.com/vGJJHXF.png)

**Nonprimary PCI**

•Rescue PCI if shock, unstable, failed reperfusion, or persistent sx (_NEJM_ 2005;353:2758)

•Routine angio ± PCI w/in 24 h of successful lysis: ↓ D/MI/revasc (_Lancet_ 2004;364:1045) and w/in 6 h ↓ reMI, recurrent ischemia, & HF compared to w/in 2 wk (_NEJM_ 2009;360:2705);

∴ _if lysed at non-PCI-capable hosp., consider transfer to PCI-capable hosp. ASAP espec if hi-risk (eg, ant. MI, IMI w/_ ↓ _EF or RV infarct, extensive STE/LBBB, HF_, ↓ _BP or_ ↑ _HR)_

•_Late_ PCI (median day 8) of occluded infarct-related artery: no benefit (_NEJM_ 2006;355:2395)

![](https://i.imgur.com/jF2XxFB.png)
Adapted from ACC/AHA 2013 STEMI Guidelines Update (_Circ_ 2013;127:529); _Lancet_ 2013;382:633

![](https://i.imgur.com/rTVwNYk.png)
Fondaparinux can be used (if CrCl >30 mL/min) in setting of lysis, where superior to UFH w/ less bleeding (_JAMA_ 2006;295:1519). Adapted from ACC/AHA 2013 STEMI Guidelines (_Circ_ 2013;127:529; _Lancet_ 2013;382:633)

**LV failure** (occurs in ~25%)

•Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O2 demand

•↓ Afterload → ↑ stroke volume & CO, ↓ myocardial O2 demand. Can use IV NTG or nitroprusside (although risk of coronary steal) → short-acting ACEI.

•Inotropes if HF despite diuresis & ↓ afterload; use dopamine, dobutamine, or milrinone

•**Cardiogenic shock** (~7%) = MAP <60 mmHg, CI <2.2 L/min/m2, PCWP >18 mmHg.

If not done already, coronary revasc (_NEJM_ 1999;341:625)

Support w/ inotropes or mechanical circulatory support to keep CI >2

**Intraaortic balloon pump (IABP)** counterpulsation offers ~0.5 L/min CO and ↑ coronary perfusion, but no survival benefit if early revasc (_NEJM_ 2012;367:1287)

**Axial flow pumps (eg, Impella)** offer up to 3–5 L/min CO, but no data that improves clinical outcomes (_JACC_ 2017;69:278)

**IMI complications** (_Circ_ 1990;81:401; _NEJM_ 1994;330:1211; _JACC_ 2003;41:1273)

•**Heart block:** ~20%, occurs in part because RCA typically supplies AV node

40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly

Rx: atropine, epi, aminophylline (100 mg/min × 2.5 min), temp pacing wire

•**RV infarct:** proximal RCA occlusion → ↓ flow to RV marginals

Angiographically present in 30–50% of cases, but only ~1/2 clinically significant

HoTN; ↑ JVP, ⊕ Kussmaul’s; ≥1 mm STE in V4R; RA/PCWP ≥0.8; RV dysfxn on TTE

Rx: optimize preload (RA goal 10–14 mmHg; _BHJ_ 1990;63:98); ↑ contractility (dobutamine); maintain AV synchrony (pacing as necessary); reperfusion (_NEJM_ 1998;338:933); mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)

* **Mechanical complications** (incid. <1% for each; typically occur a few days post-MI)
	* **Free wall rupture:** ↑ risk w/ lysis, large MI, ↑ age, ♀, HTN; p/w PEA or hypoTN, pericardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, **surgery**
	* **VSD:** large MI in elderly; AMI → apical VSD, IMI → basal septum; 90% w/ harsh murmur ± thrill (_NEJM_ 2002;347:1426); Rx: diuretics, vasodil., inotropes, IABP, **surgery**, perc. closure
	* **Papillary muscle rupture:** more common after IMI (PM pap m. supplied by PDA alone) than AMI (AL supplied by OMs & diags); 50% w/ new murmur; ↑ _v_ wave in PCWP tracing; asymmetric pulmonary edema on CXR. Rx: diuretics, vasodilators, IABP, **surgery**.
	* **AF** (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin
	* **VT/VF:** lido or amio × 6–24 h, then reassess; ↑ βB as tol., replete K & Mg, r/o ischemia;
	* Accelerated idioventricular rhythm (AIVR): slow VT (<100 bpm), often seen after
	* **Backup transcutaneous _or_ transvenous pacing** if: 2° AVB type II; BBB + AVB
	* **Transvenous pacing** if: 3° AVB; new BBB + 2° AVB type II; alternating LBBB/RBBB

